Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies for biomarker-specific patient populations. Calithera is advancing a pipeline of investigational small molecules targeting genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers with a high unmet need. The oral SYK inhibitor, mivavotinib, is being studied in R/R non-GCB DLBCL. Sapanisertib, an oral mTORC1/2 inhibitor, is being evaluated in R/R NRF2m sqNSCLC.